Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF), Ryzneuta, to treat chemotherapy-induced Neutropenia (CIN) in cancer patients. Ryzneuta is the first non-pegylated G-CSF approved by both the USFDA and China's National Medical Products Administration (NMPA). The drug was in-licensed by Aurobindo's subsidiary Acrotech Biopharma last year. Acrotech is preparing to commercialize Ryzneuta, with Aurobindo Pharma expecting more regulatory approvals in the near future.
Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF), Ryzneuta, to treat chemotherapy-induced Neutropenia (CIN) in cancer patients. Ryzneuta is the first non-pegylated G-CSF approved by both the USFDA and China's National Medical Products Administration (NMPA). The drug was in-licensed by Aurobindo's subsidiary Acrotech Biopharma last year. Acrotech is preparing to commercialize Ryzneuta, with Aurobindo Pharma expecting more regulatory approvals in the near future.
टिप्पणियाँ
एक टिप्पणी भेजें